A new approach for neurodegenerative diseases

Innovative technology

AmyPore is a Biotechnology company that designs therapeutic peptides with the aim of developing treatments for neurodegenerative diseases: Alzheimer's disease & Parkinson's disease.

News

Students in Neurosciences speak about AmyPore

05 novembre 2018

Press release November 2018

Looking for Partnership(s) to make our solution a reality, in a very ambitious schedule !

AmyP53

New therapeutic strategy

Alzheimer & Parkinson

Our main product, AmyP53, is a therapeutic peptide derived from scientific research.

Its design is based on an innovative strategy based on molecular modeling applied to neuroscience. This strategy has made it possible to combine, in a multi-parameter specification: targeting of a fundamental mechanism common to Alzheimer's and Parkinson's diseases, low-dose therapeutic action, absence of side effects at this stage of the research, administration not invasive (nasal spray).

AmyP53 is the first representative of a new therapeutic class capable of treating Alzheimer’s and Parkinson’s diseases.

20 years of Neuroscience Research
2 renowned inventors

Pr. Nouara Yahi
Pr. Jacques Fantini
New target

Neurotoxic oligomers
Administered by nasal spray
Deployable on a global scale
A unique strategy for 2 diseases

Alzheimer & Parkinson

Our approach

An innovative strategy resulting from neuroscience research

Understanding the mechanisms responsible for Alzheimer’s and Parkinson’s diseases to lead us to innovative treatments. Develop a new therapeutic class.

Our concept:

New therapeutic target

The AmyP53 solution

Scientific publications

AmyP53 is active on neurons and astrocytes 

AmyP53 is active on neurons and astrocytes 

Who are we ?

AmyPore is a Biotech founded in 2018 on the basis of the scientific discoveries of Pr. Nouara Yahi and Jacques Fantini, researchers in molecular neuroscience at the University of Aix-Marseille. 

Our sponsors

AmyPore is supported by the European Commission, Kedge Business School and the inter-university incubator IMPULSE. 

The company obtained a grant H2020 SME Phase 1.

News

Follow all our news

AmyPore is currently performing the last preclinical tests to launch its first clinical trial in humans as early as 2021

News

News

Students in Neurosciences speak about AmyPore

Press release

Next to come